Participants receive four single-dose vials per month.
Otherwise, the prices increase to $599 and $699, respectively.
Lilly started selling self-administered 2.5-milligram and 5-milligram vials last August.
Photo Illustration by Amelia Manley for Verywell Health; Eli Lilly
This includes people who previously used compounded tirzepatide.
Telehealth companies like Hims & Hers and Ro partnered with compounding pharmacies to sell off-brand tirzepatide to their members.
Providers usually prescribe a compounded medication when a patient needs a different dose or formula than the approved drug.
In the case of GLP-1 drugs, compounded versions are often much cheaper than branded ones.
In December, the FDA saidthe tirzepatide shortage had been resolvedand removed it from the shortage list.
This week, the FDA also removed Ozempic and Wegovy from the drug shortage list.
The agency gave compounding pharmacies a 30- to 60-day off-ramp period to help patients transition to the brand-name version.
Patients using Lillys self-pay program receive single-dose vials instead.
They must use a syringe and needle to draw up the medication and inject themselves.
Compounded tirzepatide products may contain different ingredients depending on the pharmacy that made it.
Vasagar said that patients may experience different side effects when transitioning from a compounded version to the brand-name version.
Both the branded and the compounded medications require physician oversight and a prescription, she said.
PR Newswire.Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients.
Pharmacy Times.FDA ends semaglutide shortage listing, contributing to ongoing legal challenges.
Food and Drug Administration.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
